Last reviewed · How we verify
Skin and Skin Structure Infections — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Test formulation (Treatment A) | test-formulation-treatment-a | Pfizer | Enzyme inhibitor | Specific enzyme | Not yet determined | |
| Piperacillin And Tazobactam | Piperacillin Sodium | Pfizer | Penicillin-class antibacterial with beta-lactamase inhibitor | Bacterial cell wall; beta-lactamase enzyme | 1981-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 2 drugs in Skin and Skin Structure Infections
- · 1 drug in Skin and Skin Structure Infections
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Skin and Skin Structure Infections:
- Skin and Skin Structure Infections treatment updates — RSS
- Skin and Skin Structure Infections treatment updates — Atom
- Skin and Skin Structure Infections treatment updates — JSON
Cite this brief
Drug Landscape (2026). Skin and Skin Structure Infections — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/skin-and-skin-structure-infections. Accessed 2026-06-09.
Related
- Skin and Skin Structure Infections full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing